Abstracts tagged "autoimmune diseases"

Abstract Number: L01 • ACR Convergence 2024
Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases
Matthew Martin¹, Erik Wilker¹, Diana Gikunju¹, Usha Narayanan¹, Unnati Pandya¹, Vijetha Prakash¹, Ashley Edwards¹, Sameer Kawatkar¹, Tenghui Chen¹, Ragunath Chandran¹, Sai Sunder¹, Sumathi Biradar¹, Joerg Distler², Alexandra Joseph¹, Stephanos Ioannidis¹ and Bhavatarini Vangamudi¹, ¹Exo Therapeutics, Cambridge, MA, ²Exo Therapeutics, Düsseldorf, Germany
Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…
Abstract Number: L03 • ACR Convergence 2024
CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus
Kyleigh Brimmer¹, Olivia Antao¹, Daniel Mayer¹, Gina Sanchez¹, Rebecca Francis¹, Htay Htay Kyi², Mary Salim², Boyan Xia², Eugenio Capitle² and Jason Weinstein¹, ¹Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, ²Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
Abstract Number: L10 • ACR Convergence 2024
Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study
John Tesser¹, Joshua June², Pendleton Wickersham³, Jane Box⁴, Guillermo Valenzuela⁵, Angela Crowley⁶, Nikila Kumar⁷, Norman Gaylis⁸, Gordan Lam⁹, David Ridley¹⁰, Gineth Paola Pinto-Patarroyo¹¹ and David Chernoff¹², ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Great Lakes Center of Rheumatology, Lansing, MI, ³Arthritis Associates PA, San Antonio, TX, ⁴DJL Clinical Research, PLLC, Charlotte, NC, ⁵Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, ⁶Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁷Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, ⁸Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁹Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹Annapolis Rheumatology, Fairfax, VA, ¹²SetPoint Medical, Sausalito, CA
Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
Abstract Number: L12 • ACR Convergence 2024
A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity
Chunli Mei¹, Xin Guan¹, Bin Wu², Mengjiao Li¹, Xiaojing Liu¹, Xi Chen¹, You Song¹, Weiwei Wang¹, Cheng Wang¹, Huiling Mei¹, Xiaoru Duan¹, Lijuan Jiang¹, Wenlin Qiu¹, Likai Yu¹, Yuhong Liu¹, Xing Zhao³, Xuanfan Zhong³, Shengjie Xue³, Wuzhong Shen³, Ying Tan³, Guojian Yu³, Guiyun Tu³, Hanyang Chen³, Amy Sun³, Xiaoqiang Yan³, Anbing Huang¹, Rong Du¹ and Qiubai Li¹, ¹Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, ³ITabMed Ltd. Changchun, Shanghai, China
Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
Abstract Number: L19 • ACR Convergence 2024
Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials
Alexei Grom¹, Uwe Ullman², Adnan Mahmood³, Josefin Blomkvist³, Brian Jamieson⁴ and Fabrizio De Benedetti⁵, ¹Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ²Sobi, Basel, Switzerland, ³Sobi, Stockholm, Sweden, ⁴Sobi, Inc., Morrisville, NC, ⁵Bambino Gesu Children's Hospital, Rome, Italy
Background/Purpose: MAS is a life-threatening complication of Still’s disease, characterized by interferon-gamma (IFNg)-driven macrophage activation and systemic hyperinflammation. Emapalumab, an anti-IFNg antibody, binds free and…
Abstract Number: 0005 • ACR Convergence 2024
Autoantibodies Identified in Myositis-Specific Autoantibody Negative Juvenile Myositis Patients
FIONNUALA MCMORROW¹, Lisa Rider², Neil McHugh¹ and Sarah Tansley¹, ¹University of Bath, Bath, United Kingdom, ²NIEHS, NIH, Garrett Park, MD
Background/Purpose: Myositis autoantibodies are important clinical biomarkers however, around 40% of patients with juvenile myositis (JM) are classified as ‘autoantibody negative’ (1) and therefore cannot…
Abstract Number: 0088 • ACR Convergence 2024
Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR
Aric Frantz¹, Romina Riener¹, Annabel Wang¹, Yanjie Bao¹, Yan Zhang¹, Daiki Matsuda¹, John Li¹, David Chu¹, Theresa Hunter¹, Qian Chen Yong¹, Michelle Nguyen¹, Stuart Sievers¹, Duy Nguyen¹, Scott Roberts¹, Diana Galvan¹, Jerel Boyd Vega¹, Matthew Butcher¹, Stanley Zhang¹, Stephen Flynn¹, Yi Kuo¹, Steven Tanis¹, John Scholler², Gregor Adams¹, Michael Rosenzweig¹, Priya Karmali¹, Adrian Bot¹, Carl June² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease indications.…
Abstract Number: 0247 • ACR Convergence 2024
Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study
Sandra Pasoto¹, Isabele Antonelli¹, Ana Cristina Medeiros-Ribeiro², Nadia Aikawa³, Leonard Kupa¹, Eduardo Borba¹, Luciana Seguro⁴, Emily Figueiredo Neves Yuki¹, ANA PAULA ASSAD¹, Carla Saad⁴, Andrea Shimabuco⁴, Andrea Negrini¹, Julia Medeiros¹, Talita Ribeiro¹, Samuel Shinjo⁴, Percival Sampaio-Barros⁴, Danieli Andrade⁵, Fernando Souza⁴, Renata Miossi⁴, Clovis Silva⁶ and Eloisa Bonfa¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵University of São Paulo, São Paulo, SP, Brazil, ⁶Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Recently, it was demonstrated that temporarily halting mycophenolate mofetil (MMF) for 1-week post-COVID-19 vaccination in systemic lupus erythematosus (SLE) patients improved humoral response, without…
Abstract Number: 0311 • ACR Convergence 2024
Investigation of Sarcoidosis-associated Neuropathy: Challenges with Diagnosis of Small Fiber Neuropathy
Kristen Caldwell¹, Sindhuja Koppu¹, Kelly Gwathmey¹, Aamer Syed¹, Jordana Kron¹, Thomas Iden¹ and Huzaefah Syed², ¹Virginia Commonwealth University, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: Small fiber neuropathy (SFN) is an underrecognized complication of sarcoidosis which can significantly impair individuals’ physical functioning and quality of life. Diagnosis includes both…
Abstract Number: 0475 • ACR Convergence 2024
Rheumatoid Arthritis – Progressive Interstitial Lung Disease with Abatacept: Data from a Large National Multicenter Cohort
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Libe Ibarrola Paino³, Ivette Casafont-Sole⁴, Jesús Loarce⁵, Juan María Blanco Madrigal⁶, Santos Castañeda⁷, Rafaela Ortega-Castro⁸, Natalia Mena Vázquez⁹, Nuria Vegas Revenga¹⁰, Lucia Cristina Dominguez Casas¹¹, Cilia Peralta Ginés¹², Carolina Diez Morrondo¹³, Lorena Pérez Albadalejo¹⁴, Rubén López Sánchez¹⁵, MARIA GUADALUPE MANZANO CANABAL¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez Viejo¹⁸, Gema Bonilla¹⁹, Olga Maíz Alonso²⁰, Carmen Carrasco-Cubero²¹, Marta Garijo Bufort²², Mireia Moreno Martinez-Losa²³, Ana Urruticoechea-Arana²⁴, Sergi Ordoñez²⁵, Carmen González Montagut²⁶, Andrea García-Valle²⁷, Juan Ramón De Dios²⁸, Patricia Carreira²⁹, Tomás Vázquez Rodríguez³⁰, Delia Fernández-Lozano³¹, Ignacio Brana Abascal³², Rafael Benito Melero-Gonzalez³³, Emilio Giner³⁴, Virginia Ruiz Esquide³⁵, Clara Ventin Rodriguez³⁶, Marina Rodriguez³⁷, Pablo Andújar-Brazal³⁸, Julia Fernandez Melon³⁹, Lilian M. López-Núñez⁴⁰, JOSE RAMON LAMUA RIAZUELO⁴¹, Carlos Fernández Díaz⁴², Javier Loricera⁴³ and Ricardo Blanco-Alonso⁴⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Rheumatology Division, Bisadoa Hospital, Bidasoa, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁶Basurto University Hospital, Bilbao, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁹IBIMA, Málaga, Andalucia, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Hospital Universtario San Agustin, Oviedo, Spain, ¹²Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹³Hospital de Leon, León, Spain, ¹⁴Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ¹⁶CAZA, Salamanca, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Hospital Severo Ochoa, Madrid, Madrid, Spain, ¹⁹H. Universitario La Paz, Madrid, Spain, ²⁰3Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, ²¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²⁴Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, ²⁵Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain, ²⁶Hospital Universitario de Valladolid, Valladolid, Spain, ²⁷Hospital General Río Carrión, Palencia, Spain, ²⁸Osakidetza, Vitoria, Spain, ²⁹Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ³⁰Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, ³¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ³²Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ³³CHU Ourense, O Carballino, Spain, ³⁴Hospital Royo Villanova, Teruel, Spain, ³⁵Hospital Clinic Barcelona, Barcelona, Spain, ³⁶Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³⁷Hospital Clínico Universitario de Santiago, La Coruna, Spain, ³⁸Hospital Universitario Doctor Peset, Valencia, Spain, ³⁹Hospital Son Espases, Palma, Spain, ⁴⁰Hospital Universitari Son Llàtzer, Palma, Spain, ⁴¹Hospital Universitario del Henares, Madrid, Spain, ⁴²Hospital Universitario Santa Lucía, Cartagena, Spain, ⁴³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated effectiveness in the treatment of RA-ILD, regardless…
Abstract Number: 0703 • ACR Convergence 2024
Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Andrew Sternlicht¹, Michael Shanahan², Erin Morton², Meredith Todd³, Ivana Hunt², Zoey Reed², amanda weragoda⁴, Lashika Weerakoon² and Elizabeth Briggs², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Flinders Medical Centre, Adelaide, Australia, ³Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia, ⁴F, Adelaide, Australia
Background/Purpose: While 95% of Systemic Sclerosis (SSc) patients have Raynaud’s phenomenon(RP) and many patients rate it as the most bothersome and severe symptom of their…
Abstract Number: 0841 • ACR Convergence 2024
Clinical and Biologic Predictors of Thrombosis in Persistently Antiphospholipid Antibody Positive Patients: Prospective Analysis of the International APS ACTION Clinical Database and Repository (“Registry”)
Jonathan Thaler¹, Michael Parides¹, Danieli Andrade², Diana Paredes-Ruiz³, Maria Tektonidou⁴, Vittorio Pengo⁵, Savino Sciascia⁶, Cecilia Nalli⁷, Guilherme Ramires de Jesús⁸, Paul Fortin⁹, Maria Efthymiou¹⁰, H Michael Belmont¹¹, Michelle Petri¹², Ricard Cervera¹³, Leslie Skeith¹⁴, TATSUYA ATSUMI¹⁵, Chary Lopez-Pedrera¹⁶, Yu Zuo¹⁷, David Branch¹⁸, Rohan Willis¹⁹, Nina Kello²⁰, Zhuoli Zhang²¹, Esther Rodriguez-Almaraz²², Bahar Artim Esen²³, Jose Pardos-Gea²⁴, Guillermo Pons-Estel²⁵, Giulia Pazzola²⁶, Hui Shi¹⁷, Ali Duarte-Garcia²⁷, Medha Barbhaiya¹, Cécile Yelnik²⁸, Pierluigi Meroni²⁹, Robert Roubey³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³², Jacob Rand³³ and Doruk Erkan¹, and on behalf of APS ACTION, ¹Hospital for Special Surgery, New York, NY, ²University of São Paulo, São Paulo, SP, Brazil, ³Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ⁶University of Turin, Torino, Turin, Italy, ⁷ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁸Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ⁹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁰University College London, London, United Kingdom, ¹¹NYU School of Medicine, New York, NY, ¹²Johns Hopkins University School of Medicine, Timonium, MD, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴University of Calgary, Calgary, ON, Canada, ¹⁵Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁹University of Texas Medical Branch, Galveston, TX, ²⁰Northwell Health, Brooklyn, NY, ²¹Peking University First Hospital, Beijing, China, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁴Vall d'Hebron University Hospital, Barcelona, Spain, ²⁵CREAR, Rosario, Argentina, ²⁶Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²⁷Mayo Clinic, Rochester, MN, ²⁸lille university, Lille, France, ²⁹IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ³⁰Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³³Weill Cornell Medical Center, Bronx, NY
Background/Purpose: There is a lack of high-quality data to inform risk-stratified long-term thrombosis prevention strategies in patients with persistently positive antiphospholipid antibodies (aPL). The APS…
Abstract Number: 0916 • ACR Convergence 2024
Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia
Mahmut Kaymakci¹, Anuya Natu², Clifford Csizmar², Terra Lasho², Christy Finke², Abhishek Mangaonkar¹, Aref Al-Kali¹, Hassan Alkhateeb¹, Jenna Fernandez², Matthew Koster¹, Cornelia Weyand², Mrinal Patnaik¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester
Background/Purpose: Somatic mutations occurring in the hematopoietic system can be associated with concomitant hematologic and inflammatory diseases. Chronic myelomonocytic leukemia (CMML) is a hematologic neoplasm…
Abstract Number: 1005 • ACR Convergence 2024
Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib
Nur Barlas, Sait Barlas, Stefan Milutinovic and Shristi Basnyat, Florida State University College of Medicine Internal Medicine Residency Program at Lee Health, Cape Coral
Background/Purpose: Janus Kinase (JAK) inhibitors are the agents of choice for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis when other DMARDs are…
Abstract Number: 1163 • ACR Convergence 2024
Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population
Aurélie Mourot¹, Beatrice Panuta¹, Juliette Charbonneau¹, Ange Mounkam Ngeuleu¹, Caroline Vo², Eric Rich³, Josiane Bourré-Tessier³, Edith Villeneuve³, Hélène Manganas³, Andréanne Gauthier³, Julie Morisset³, Sabrina Anh-Tu Hoa³ and Océane Landon-Cardinal³, ¹University of Montreal, Montreal, QC, Canada, ²Hôpital Charles Lemoyne, Montreal, QC, Canada, ³Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada
Background/Purpose: Antisynthetase syndrome (ASSD) is characterized by interstitial lung disease (ILD), myositis, polyarthritis, Raynaud’s phenomenon, dermatomyositis-like rash and mechanic’s hands. ILD may present with isolated…

1
2
3
…
80
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].